Popular on TelAve
- Natalie Jean Releases Heartfelt Tribute Single "What They Didn't See" Honoring Late Friend and Lyricist Michael Peloso
- European Tech Startup RoarFun discovers a gap in the U.S. market with a branded racing simulator rental at Atlanta's MRO Americas Aviation Convention
- Premium Domain Name "Feedri.com" Now Available for Acquisition After $8,500 Offer
- Spiritually Transformative Events Based on Bhagavad Gita – Path to a Fulfilling Life
- Carnegie Hall Hosts Theatrical Concert: El Dorado – A Musical Portrait of Edgar Allan Poe
- Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement
- Q1 2025 Revenue Soars 92% to $1.13M on Strategic Acquisitions, Organic Growth & Breakthroughs in AI Drones & Quantum Tech: ZenaTech Stock Symbol: ZENA
- $10 Million Plan to Acquire Successful Remote Lottery Platform: Expanding Global Footprint into Live Entertainment: Lottery.com (Stock Symbol: LTRY)
- Assent Launches Carbon Border Adjustment Mechanism Solution to Help Manufacturers Meet Regulatory Requirements
- Degrees of Justice: Attorney Frank Walker Charts the Future of Criminal Justice with Ph.D Degree
Similar on TelAve
- OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
- KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
- purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
- purelyIV Launches Mobile Iron Infusion Therapy for Patients with Iron Deficiency Anemia
- Smile Makers Dental Care Introduces FP1: East Bay's First Robotic-Assisted Full-Arch Implant Solution for Natural, Fixed Smiles
- DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
- Fray Fitness and Truemed Partner to Enable HSA/FSA-Funded Fitness Equipment Purchases
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- AI changes cryptocurrency market trading, TWL Miner launches new 1-day contract, giving away over $1 million
- A Global First: NaturismRE™ Launches the Global Urgency Index
418,000 Kids Aged 0-5 on Psych Drugs: Campaign for "De-Prescribing"
TelAve News/10848545
Mental health watchdog launches new campaign to obtain "zero tolerance" for the psychotropic drugging of children, some too young to even walk
LOS ANGELES - TelAve -- In commemoration of Universal Children's Day in November and Human Rights Day on December 10th, the Citizens Commission on Human Rights International launched a new campaign in the U.S. aimed at securing legislative and policymaker support for a zero-tolerance approach to psychotropic drugging of children. CCHR is deeply concerned by the 6.1 million children in America prescribed psychotropic drugs in 2020, including 418,425 in the 0–5 age group. The group obtained this data from IQVIA (formerly IMS Health), the largest vendor of U.S. physician prescribing data. While these alarming figures reflect the broader scope of psychotropic drugging, government programs such as Medicaid and Children's Health Insurance Program (CHIP) are funding what CCHR deems "child abuse" as infants, toddlers and preschoolers are subjected to powerful drugs that can pose serious, long-term risks to their health and development.
In 2023, 6.5 million Medicaid/Children's Health Insurance Program (CHIP) beneficiaries were ages 0-2 and a further 20.6 million were aged 3-11. CCHR says there needs to be a massive overhaul of Medicaid and CHIP, which has become a lucrative system for those prescribing mind-altering drugs to millions of children—some so powerful they can drive them to suicide and acts of violence. Medicaid and CHIP are the largest payers for mental health services and substance abuse treatment.[1]
CCHR wants to see the adoption of policies similar to those in the United Kingdom to start reducing the drugging of children. In the UK, a group of about 30 medical experts and politicians discovered "Rising antidepressant prescribing is not associated with an improvement in mental health outcomes at the population level, which, according to some measures, have worsened as antidepressant prescribing has risen." They called for a reversal in the rate of antidepressant prescribing (de-prescribing) which includes, stopping the prescribing of antidepressants for mild conditions for new patients, proper informed consent and regular review of harms, as well as funding and delivering a national 24-hour prescribed drug withdrawal helpline and website.[2]
More on TelAve News
The group says that policies must encompass all psychotropic drugs. Medicaid administration programs have attempted to address the massive prescribing of antipsychotics and other psychotropics in children and adolescents, particularly foster care youth, following government reports highlighting excessive use. Consequently, some state Medicaid oversight programs have published research indicating a reduction in antipsychotic use among children, according to Julie Zito, a professor of Pharmacy and Psychiatry at the University of Maryland, and her colleagues in Frontiers in Psychiatry.[3] However, CCHR questions the accuracy of these reduction claims.
In 2023, a study published in Health Affairs did show there was a sizeable 43% decline in antipsychotic use among children aged 2–17 under Medicaid between 2008 and 2016. The largest absolute decline was observed in White children (−1.37%) vs. Black (−0.62%), Hispanic (−0.31%), and Asian (−0.17%) children.[4]
However, for children in foster care, antipsychotic use was still overrepresented. Although slightly decreased, in 2016, 7.7% were prescribed the drugs compared to 1.19% not in foster care. The researchers warned that antipsychotics are associated with potentially serious side effects, including type 2 diabetes, cardiometabolic effects (such as high blood pressure, weight gain, cholesterol problems, etc.), and unexpected death.
Antipsychotics have consistently ranked among the top drug classes for Medicaid spending across all age groups. In 2019, psychotherapeutic agents—including antipsychotics and antidepressants—were the third most expensive outpatient drug class for the program. That year, antipsychotics represented 9% of Medicaid's total spending ($6.2 billion) and 10% of all prescriptions (73.1 million claims). Between 2016 and 2021, the total number of antipsychotic prescription claims rose by 23.3% from 18.5 million. Similarly, total gross spending on these drugs increased by 16.7%, climbing from $5.17 billion in 2016 to $6.03 billion in 2021.[5]
Children in the welfare system are also a target for these drugs. A 2023 study published in JAMA Pediatrics analyzed the prevalence of psychotropic drug use and polypharmacy—the practice of prescribing two or more drugs—among Medicaid beneficiaries and children in the child welfare system. This latter group included youth accessing adoption assistance, foster care, or guardianship care.
More on TelAve News
Researchers estimated the rates of psychotropic drug use, polypharmacy, and associated mental health conditions by age group (3-17, 3-5, 6-11, and 12-17 years)."
Findings revealed that 26.25% of children in the child welfare group had been prescribed at least one psychotropic drug, and 13.27% experienced polypharmacy. By comparison, 9.06% of other Medicaid-enrolled youths were prescribed psychotropic drugs, with only 3.11% experiencing polypharmacy.
The most common class of psychotropic drugs in the child welfare group was stimulants (15.95%), followed by antidepressants (9.88%) and antipsychotics (7.87%).[6]
Psychotropic polypharmacy also affects substantially more children and adolescents today than has been the case, Julie Zito, Ph.D. reported. As many as 300,000 youth now receive three or more classes concomitantly. The duration of concomitant use is relatively long, e.g., 69–89% of annual medicated days. More adverse event reports are associated with 3-class compared with 2-class drug regimens.[7]
Supporting a zero-tolerance de-escalation policy should include warning parents and caregivers of children in the welfare and Medicaid-CHIP populations about the critical adverse drug effects. This information is concisely presented in FDA-approved Medication Guides—handouts provided with many prescriptions—designed to help consumers recognize and avoid serious adverse events.
Both state and federal governments are urged to adopt a strong policy of "de-prescribing" powerful psychotropic drugs to children and adolescents.
By prioritizing these measures, the U.S. can take significant steps toward safeguarding the well-being of its youngest and most vulnerable populations, protecting them from harmful psychotropic drugs.
Sources:
[1] www.medicaid.gov/medicaid/quality-of-care/downloads/beneficiary-ataglance-2023.pdf
[2] www.bmj.com/content/383/bmj.p2730
[3] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
[4] pmc.ncbi.nlm.nih.gov/articles/PMC10845053/
[5] link.springer.com/article/10.1007/s11414-024-09889-0
[6] pmc.ncbi.nlm.nih.gov/articles/PMC10442784/
[7] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
In 2023, 6.5 million Medicaid/Children's Health Insurance Program (CHIP) beneficiaries were ages 0-2 and a further 20.6 million were aged 3-11. CCHR says there needs to be a massive overhaul of Medicaid and CHIP, which has become a lucrative system for those prescribing mind-altering drugs to millions of children—some so powerful they can drive them to suicide and acts of violence. Medicaid and CHIP are the largest payers for mental health services and substance abuse treatment.[1]
CCHR wants to see the adoption of policies similar to those in the United Kingdom to start reducing the drugging of children. In the UK, a group of about 30 medical experts and politicians discovered "Rising antidepressant prescribing is not associated with an improvement in mental health outcomes at the population level, which, according to some measures, have worsened as antidepressant prescribing has risen." They called for a reversal in the rate of antidepressant prescribing (de-prescribing) which includes, stopping the prescribing of antidepressants for mild conditions for new patients, proper informed consent and regular review of harms, as well as funding and delivering a national 24-hour prescribed drug withdrawal helpline and website.[2]
More on TelAve News
- purelyIV Launches Mobile Iron Infusion Therapy for Patients with Iron Deficiency Anemia
- Smile Makers Dental Care Introduces FP1: East Bay's First Robotic-Assisted Full-Arch Implant Solution for Natural, Fixed Smiles
- DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
- Fibrecross Unveils Next-Generation 800G Optical Transceiver
- GMO Miner: Creating a simple, efficient and reliable new cloud mining experience
The group says that policies must encompass all psychotropic drugs. Medicaid administration programs have attempted to address the massive prescribing of antipsychotics and other psychotropics in children and adolescents, particularly foster care youth, following government reports highlighting excessive use. Consequently, some state Medicaid oversight programs have published research indicating a reduction in antipsychotic use among children, according to Julie Zito, a professor of Pharmacy and Psychiatry at the University of Maryland, and her colleagues in Frontiers in Psychiatry.[3] However, CCHR questions the accuracy of these reduction claims.
In 2023, a study published in Health Affairs did show there was a sizeable 43% decline in antipsychotic use among children aged 2–17 under Medicaid between 2008 and 2016. The largest absolute decline was observed in White children (−1.37%) vs. Black (−0.62%), Hispanic (−0.31%), and Asian (−0.17%) children.[4]
However, for children in foster care, antipsychotic use was still overrepresented. Although slightly decreased, in 2016, 7.7% were prescribed the drugs compared to 1.19% not in foster care. The researchers warned that antipsychotics are associated with potentially serious side effects, including type 2 diabetes, cardiometabolic effects (such as high blood pressure, weight gain, cholesterol problems, etc.), and unexpected death.
Antipsychotics have consistently ranked among the top drug classes for Medicaid spending across all age groups. In 2019, psychotherapeutic agents—including antipsychotics and antidepressants—were the third most expensive outpatient drug class for the program. That year, antipsychotics represented 9% of Medicaid's total spending ($6.2 billion) and 10% of all prescriptions (73.1 million claims). Between 2016 and 2021, the total number of antipsychotic prescription claims rose by 23.3% from 18.5 million. Similarly, total gross spending on these drugs increased by 16.7%, climbing from $5.17 billion in 2016 to $6.03 billion in 2021.[5]
Children in the welfare system are also a target for these drugs. A 2023 study published in JAMA Pediatrics analyzed the prevalence of psychotropic drug use and polypharmacy—the practice of prescribing two or more drugs—among Medicaid beneficiaries and children in the child welfare system. This latter group included youth accessing adoption assistance, foster care, or guardianship care.
More on TelAve News
- DOT Miners launches a new cloud mining platform: low threshold, high transparency, and helps promote the inclusion of global digital assets
- Fray Fitness and Truemed Partner to Enable HSA/FSA-Funded Fitness Equipment Purchases
- Crazy Discount Codes App Transforms Mobile Shopping With Real-Time Deals
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- As Sober.Buzz Community Explodes It's Growth Globally it is Announcing "Spreading the Good BUZZ" Podcast Hosted by Josh Case Debuting July 7th
Researchers estimated the rates of psychotropic drug use, polypharmacy, and associated mental health conditions by age group (3-17, 3-5, 6-11, and 12-17 years)."
Findings revealed that 26.25% of children in the child welfare group had been prescribed at least one psychotropic drug, and 13.27% experienced polypharmacy. By comparison, 9.06% of other Medicaid-enrolled youths were prescribed psychotropic drugs, with only 3.11% experiencing polypharmacy.
The most common class of psychotropic drugs in the child welfare group was stimulants (15.95%), followed by antidepressants (9.88%) and antipsychotics (7.87%).[6]
Psychotropic polypharmacy also affects substantially more children and adolescents today than has been the case, Julie Zito, Ph.D. reported. As many as 300,000 youth now receive three or more classes concomitantly. The duration of concomitant use is relatively long, e.g., 69–89% of annual medicated days. More adverse event reports are associated with 3-class compared with 2-class drug regimens.[7]
Supporting a zero-tolerance de-escalation policy should include warning parents and caregivers of children in the welfare and Medicaid-CHIP populations about the critical adverse drug effects. This information is concisely presented in FDA-approved Medication Guides—handouts provided with many prescriptions—designed to help consumers recognize and avoid serious adverse events.
Both state and federal governments are urged to adopt a strong policy of "de-prescribing" powerful psychotropic drugs to children and adolescents.
By prioritizing these measures, the U.S. can take significant steps toward safeguarding the well-being of its youngest and most vulnerable populations, protecting them from harmful psychotropic drugs.
Sources:
[1] www.medicaid.gov/medicaid/quality-of-care/downloads/beneficiary-ataglance-2023.pdf
[2] www.bmj.com/content/383/bmj.p2730
[3] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
[4] pmc.ncbi.nlm.nih.gov/articles/PMC10845053/
[5] link.springer.com/article/10.1007/s11414-024-09889-0
[6] pmc.ncbi.nlm.nih.gov/articles/PMC10442784/
[7] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
Source: Citizens Commission on Human Rights
0 Comments
Latest on TelAve News
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com
- The internet home telephone services and tv channels
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
- Integris Composites Joins Paris Air Show at USA Pavilion
- Cheryl Hines' Trailer PROWLING to Sardinia
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
- Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
- DivX Enhances AVI Playback Resources; Simplifies Guide to Playing AVI Files with DivX Software
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
- Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
- Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers